| Ms Melissa S Rouse, | |
|
1130 Medical Pl, Seymour, IN 47274-2640 | |
| (812) 519-1552 | |
| (812) 519-1774 |
| Full Name | Ms Melissa S Rouse |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 3 Years |
| Location | 1130 Medical Pl, Seymour, Indiana |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1366174203 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LF0000X | Nurse Practitioner - Family | 71012732A (Indiana) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Jackson County Schneck Memorial Hospital | 8224004585 | 108 |
News Archive
Vanderbilt University announced Oct. 21 that it has received a $100,000 Grand Challenges Explorations grant from the Bill & Melinda Gates Foundation. The grant will support an innovative global health research project conducted by Associate Professor of Chemistry David Wright and Professor of Biomedical Engineering Rick Haselton, titled "Coffee Ring Stain Diagnostics for Malaria."
With rise of incidence of flu this winter emergency stocks of the vaccine are being released. A review is to be carried out into whether vaccines should be purchased centrally next year in order to avoid shortages. At present the GPs can procure the jabs directly from manufacturers according to their estimates of patient requirement.
BioSyent Inc. ("BioSyent") (TSX VENTURE:RX) announces that its subsidiary BioSyent Pharma Inc. has signed an exclusive product development, supply and distribution agreement with a new partner for a new product under its Hospital Products Division.
Targeting cancer stem cells may be a more effective way to overcome cancer resistance and prevent the spread of squamous cell carcinoma — the most common head and neck cancer and the second-most common skin cancer, according to a new study by cancer researchers at the UCLA School of Dentistry.
Aegerion Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the development and commercialisation of novel, life-altering therapies for patients with debilitating, often fatal, rare diseases, announced today that the European Commission has authorised Lojuxta (lomitapide) hard capsules as an adjunct to a low-fat diet and other lipid-lowering medicinal products with or without low density lipoprotein apheresis in adult patients with homozygous familial hypercholesterolaemia.
› Verified 7 days ago
| Entity Name | Jackson County Schneck Memorial Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1629143037 PECOS PAC ID: 8224004585 Enrollment ID: O20041029000584 |
News Archive
Vanderbilt University announced Oct. 21 that it has received a $100,000 Grand Challenges Explorations grant from the Bill & Melinda Gates Foundation. The grant will support an innovative global health research project conducted by Associate Professor of Chemistry David Wright and Professor of Biomedical Engineering Rick Haselton, titled "Coffee Ring Stain Diagnostics for Malaria."
With rise of incidence of flu this winter emergency stocks of the vaccine are being released. A review is to be carried out into whether vaccines should be purchased centrally next year in order to avoid shortages. At present the GPs can procure the jabs directly from manufacturers according to their estimates of patient requirement.
BioSyent Inc. ("BioSyent") (TSX VENTURE:RX) announces that its subsidiary BioSyent Pharma Inc. has signed an exclusive product development, supply and distribution agreement with a new partner for a new product under its Hospital Products Division.
Targeting cancer stem cells may be a more effective way to overcome cancer resistance and prevent the spread of squamous cell carcinoma — the most common head and neck cancer and the second-most common skin cancer, according to a new study by cancer researchers at the UCLA School of Dentistry.
Aegerion Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the development and commercialisation of novel, life-altering therapies for patients with debilitating, often fatal, rare diseases, announced today that the European Commission has authorised Lojuxta (lomitapide) hard capsules as an adjunct to a low-fat diet and other lipid-lowering medicinal products with or without low density lipoprotein apheresis in adult patients with homozygous familial hypercholesterolaemia.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ms Melissa S Rouse, 1130 Medical Pl, Seymour, IN 47274-2640 Ph: (812) 519-1552 | Ms Melissa S Rouse, 1130 Medical Pl, Seymour, IN 47274-2640 Ph: (812) 519-1552 |
News Archive
Vanderbilt University announced Oct. 21 that it has received a $100,000 Grand Challenges Explorations grant from the Bill & Melinda Gates Foundation. The grant will support an innovative global health research project conducted by Associate Professor of Chemistry David Wright and Professor of Biomedical Engineering Rick Haselton, titled "Coffee Ring Stain Diagnostics for Malaria."
With rise of incidence of flu this winter emergency stocks of the vaccine are being released. A review is to be carried out into whether vaccines should be purchased centrally next year in order to avoid shortages. At present the GPs can procure the jabs directly from manufacturers according to their estimates of patient requirement.
BioSyent Inc. ("BioSyent") (TSX VENTURE:RX) announces that its subsidiary BioSyent Pharma Inc. has signed an exclusive product development, supply and distribution agreement with a new partner for a new product under its Hospital Products Division.
Targeting cancer stem cells may be a more effective way to overcome cancer resistance and prevent the spread of squamous cell carcinoma — the most common head and neck cancer and the second-most common skin cancer, according to a new study by cancer researchers at the UCLA School of Dentistry.
Aegerion Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the development and commercialisation of novel, life-altering therapies for patients with debilitating, often fatal, rare diseases, announced today that the European Commission has authorised Lojuxta (lomitapide) hard capsules as an adjunct to a low-fat diet and other lipid-lowering medicinal products with or without low density lipoprotein apheresis in adult patients with homozygous familial hypercholesterolaemia.
› Verified 7 days ago
Robin Elaine Cartwright, FNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 410 S Chestnut St, Seymour, IN 47274 Phone: 812-523-5185 | |
Ms. Rachel Elaine Hoevener, NP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 225 S Pine St, Jmb, 2nd Floor, Seymour, IN 47274 Phone: 812-523-7466 Fax: 812-523-7471 | |
Mrs. Cathy Robbins Hildebrand, RN, FNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 411 W Tipton St, Seymour, IN 47274 Phone: 812-522-0524 | |
Sarah Elizabeth Ramey, NP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 357 Tanger Blvd Ste 201b, Seymour, IN 47274 Phone: 812-523-3700 | |
Virginia Stewart-kinney, NP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 411 W Tipton St, Seymour, IN 47274 Phone: 812-522-2349 | |
Dr. Stephanie Amber Burgess, DNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 1171 W Tipton St, Suite D, Seymour, IN 47274 Phone: 812-524-8780 | |
Yvonne Carmela Lucas, MSN, RN, FNP-C Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 113 N Chestnut St Ste 100, Seymour, IN 47274 Phone: 812-524-8388 |